The MHRA typically sends a copy of the validation report confirming validation to the sponsor when they initially validate an MAA. This report is crucial for the sponsor to understand the status of their application and any necessary actions to proceed.
Here's a breakdown of what happens during validation and the information included in the report:
Validation Process:
Review: The MHRA thoroughly examines the MAA to ensure it meets all regulatory requirements, including: Completeness Formatting Compliance with guidelines Presence of necessary data and supporting documents Identifying Issues: If any deficiencies or omissions are found, the MHRA will raise them in the validation report. Communication: The MHRA sends the validation report to the sponsor, usually within 30 days of receiving the application. Validation Report Contents:
Validation status: Clearly states whether the MAA has been validated or not. List of deficiencies (if any): Details any missing information or areas that need correction. Instructions for addressing issues: Provides guidance on how to rectify any deficiencies. Timelines for resubmission: Specifies deadlines for resubmitting the corrected application. Contact information for further inquiries: Provides contact details for any questions or clarifications. Key Points:
Validation is essential: It's not an assessment of the medicine's quality, safety, or efficacy; it's a check for completeness and compliance with regulatory requirements. Sponsor's responsibility: The sponsor must address any deficiencies highlighted in the validation report and resubmit the application accordingly. Communication is key: The MHRA and sponsor should maintain open communication throughout the process to ensure timely validation and progression of the MAA. Additional Information:
MHRA guidance: The MHRA publishes detailed guidance on the validation process and requirements for MAAs. Contact the MHRA: For specific inquiries or concerns, it's always best to contact the MHRA directly.
Market Data 
Markets 
AI
